Joel Kremer
Overview
Explore the profile of Joel Kremer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
3682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spandorfer R, Kane K, Pappas D, Kremer J, Reed G, Curtis J, et al.
Semin Arthritis Rheum
. 2024 Nov;
70():152559.
PMID: 39550775
Objectives: Patients with rheumatoid arthritis (RA) are more likely to develop work disability than the general population. We investigated whether individuals younger than 65 years of age who had both...
2.
Baker J, Reed G, Kremer J
Arthritis Care Res (Hoboken)
. 2022 Oct;
75(6):1384-1385.
PMID: 36250408
No abstract available.
3.
Ferrero S, Wittoek R, Allado E, Cruzel C, Fontas E, Breuil V, et al.
Semin Arthritis Rheum
. 2021 Jun;
51(4):831-838.
PMID: 34157578
Objective: To examine the effect of methotrexate (MTX) on pain and structural progression in symptomatic erosive hand osteoarthritis (HOA). Methods: This 1-year prospective, single-centre, randomised, double-blind, placebo-controlled study (www.ClinicalTrial.gov, NCT01068405)...
4.
Fraenkel L, Bathon J, England B, St Clair E, Arayssi T, Carandang K, et al.
Arthritis Care Res (Hoboken)
. 2021 Jun;
73(7):924-939.
PMID: 34101387
Objective: To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. Methods: We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review,...
5.
Fraenkel L, Bathon J, England B, St Clair E, Arayssi T, Carandang K, et al.
Arthritis Rheumatol
. 2021 Jun;
73(7):1108-1123.
PMID: 34101376
Objective: To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. Methods: We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review,...
6.
Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann R, Geissler K, et al.
Ann Rheum Dis
. 2020 Nov;
80(1):71-87.
PMID: 33158881
Objectives: Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use...
7.
Baker J, Reed G, Kremer J
Arthritis Care Res (Hoboken)
. 2020 Oct;
74(2):229-235.
PMID: 33002323
Objective: Fluctuations in weight have been linked to cardiovascular (CV) outcomes in the general population. The present study was undertaken to evaluate whether weight fluctuation was independently predictive of CV...
8.
Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al.
Ann Rheum Dis
. 2020 Aug;
79(11):1400-1413.
PMID: 32759265
Objectives: Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of...
9.
Lee Y, Lu B, Guan H, Greenberg J, Kremer J, Solomon D
Arthritis Rheumatol
. 2020 Feb;
72(7):1082-1090.
PMID: 32103630
Objective: To identify the extent to which opioid prescribing rates for patients with rheumatoid arthritis (RA) vary in the US and to determine the implications of baseline opioid prescribing rates...
10.
Strand V, van der Heijde D, Tanaka Y, Keystone E, Kremer J, Zerbini C, et al.
Clin Exp Rheumatol
. 2019 Dec;
38(5):848-857.
PMID: 31858963
Objectives: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) ORAL Scan...